Background: Lorlatinib and Insulin Resistance

Lorlatinib is a third-generation ALK inhibitor used to treat ALK-positive NSCLC. While it has shown remarkable efficacy in overcoming resistance to earlier-generation ALK inhibitors, it comes with a spectrum of adverse effects. Hyperglycemia is among these, but the mechanism remains unclear. Is it a direct effect on pancreatic beta cells, increased insulin resistance, or a combination? The prevailing hypothesis leans towards increased insulin resistance, potentially mediated through effects on lipid metabolism. However, this case challenges the notion that all lorlatinib-induced diabetes is simply a matter of insulin resistance.

Existing guidelines, such as the NCCN guidelines for NSCLC, acknowledge hyperglycemia as a potential side effect of ALK inhibitors and recommend monitoring blood glucose levels. However, they do not specifically address the possibility of autoantibody-negative diabetes or provide guidance on how to differentiate it from other forms of drug-induced hyperglycemia. This case highlights a gap in current recommendations.

Case Presentation: A Diagnostic Puzzle

A patient with ALK-positive NSCLC, treated with lorlatinib, presented with classic symptoms of hyperglycemia - polydipsia, polyuria, and fatigue. Initial lab work confirmed significantly elevated glucose levels and the presence of ketones, indicating DKA. What made this case unusual was the absence of detectable GAD65, IA-2, and ZnT8 autoantibodies. These are the typical markers we associate with type 1 diabetes. The patient had no prior history of diabetes and no family history of autoimmune disease. So, what's going on?

Differential Diagnosis: Beyond Autoimmunity

The absence of autoantibodies narrows the differential diagnosis, but doesn't eliminate diabetes. We must consider other possibilities, including type 2 diabetes exacerbated by lorlatinib, pancreatic damage leading to insulin deficiency, or a unique form of drug-induced diabetes that doesn't trigger an autoimmune response. The authors reasonably excluded typical type 1 diabetes. They also considered the possibility of atypical forms of autoimmune diabetes, such as latent autoimmune diabetes in adults (LADA), but the acute presentation with DKA made this less likely. Drug-induced diabetes, therefore, became the most probable explanation. Lorlatinib’s impact on insulin sensitivity and glucose metabolism clearly played a central role.

Treatment and Outcome: Insulin and Lorlatinib

The patient was initially treated with intravenous insulin to resolve the DKA. Once stabilized, they were transitioned to subcutaneous insulin injections. Here's the critical question: What about the lorlatinib? The decision was made to continue lorlatinib, given its importance in controlling the patient's NSCLC. However, the insulin dose had to be carefully adjusted to maintain glycemic control. This highlights the difficult balancing act clinicians face when managing these patients. Do we prioritize cancer control or minimize the risk of metabolic complications?

Study Limitations: N of 1

Let's be clear: This is a single case report. We can't draw broad conclusions or change clinical practice based on one patient. We have no control group and no way to assess the true incidence of autoantibody-negative diabetes in patients treated with lorlatinib. Furthermore, the underlying mechanism remains speculative. Is lorlatinib directly toxic to beta cells in certain individuals? Does it trigger a non-autoimmune inflammatory response in the pancreas? These are questions that require further investigation. Additionally, the cost-effectiveness of routine autoantibody screening in all patients on lorlatinib is questionable, given the rarity of this presentation.

Clinical Implications: Cost and Monitoring